95 related articles for article (PubMed ID: 8558203)
1. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma.
Sarris AH; Younes A; McLaughlin P; Moore D; Hagemeister F; Swan F; Rodriguez MA; Romaguera J; North L; Mansfield P; Callendar D; Mesina O; Cabanillas F
J Clin Oncol; 1996 Jan; 14(1):233-9. PubMed ID: 8558203
[TBL] [Abstract][Full Text] [Related]
2. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.
Younes A; Sarris A; Melnyk A; Romaguera J; McLaughlin P; Swan F; Rodriguez MA; Hagemeister F; Moore D; North L
J Clin Oncol; 1995 Mar; 13(3):583-7. PubMed ID: 7884419
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Younes A; Preti HA; Hagemeister FB; McLaughlin P; Romaguera JE; Rodriguez MA; Samuels BI; Palmer JL; Cabanillas F
Ann Oncol; 2001 Jul; 12(7):923-7. PubMed ID: 11521796
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
5. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
Wilson WH; Bryant G; Bates S; Fojo A; Wittes RE; Steinberg SM; Kohler DR; Jaffe ES; Herdt J; Cheson BD
J Clin Oncol; 1993 Aug; 11(8):1573-82. PubMed ID: 7687667
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
Press OW; LeBlanc M; O'Rourke TJ; Gagnet S; Chapman RA; Balcerzak SP; Fisher RI
J Clin Oncol; 1998 Feb; 16(2):574-8. PubMed ID: 9469343
[TBL] [Abstract][Full Text] [Related]
7. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.
Younes A; Ayoub JP; Hagemeister FB; McLaughlin P; Sarris A; Rodriguez MA; Swan F; Romaguera JE; Martin J; Cabanillas F
J Clin Oncol; 1996 Feb; 14(2):543-8. PubMed ID: 8636769
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.
Murphy WK; Fossella FV; Winn RJ; Shin DM; Hynes HE; Gross HM; Davilla E; Leimert J; Dhingra H; Raber MN
J Natl Cancer Inst; 1993 Mar; 85(5):384-8. PubMed ID: 8094466
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
10. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.
Wilson WH; Chabner BA; Bryant G; Bates S; Fojo A; Regis J; Jaffe ES; Steinberg SM; Goldspiel BR; Cheson BD
J Clin Oncol; 1995 Feb; 13(2):381-6. PubMed ID: 7531220
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease.
Miller TP; Chase EM; Dorr R; Dalton WS; Lam KS; Salmon SE
Anticancer Drugs; 1998 Feb; 9(2):135-40. PubMed ID: 9510499
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial.
Younes A; Ayoub JP; Sarris A; Hagemeister F; North L; Pate O; McLaughlin P; Rodriguez MA; Romaguera J; Kurzrock R; Preti A; Bachier C; Smith T; Cabanillas F
Br J Haematol; 1997 Feb; 96(2):328-32. PubMed ID: 9029021
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
17. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
Rosell R; González-Larriba JL; Alberola V; Molina F; Monzó M; Benito D; Pérez JM; de Anta JM
Semin Oncol; 1995 Dec; 22(6 Suppl 14):12-8. PubMed ID: 8553077
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
Shepherd FA; Latreille J; Paul K; Eisenhauer E
Semin Oncol; 1996 Dec; 23(6 Suppl 16):84-90. PubMed ID: 9007130
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
20. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]